Search

Preterm researchers Dr Shannon Simpson (left) and Professor Jane Pillow (right) with Tony Sparks WA chairperson Amber Bates.

The Kids Research Institute Australia, Perth Children’s Hospital Foundation and Perth Children’s Hospital have formed a strategic partnership to support the establishment and operation of the Wal-yan Respiratory Research Centre.

The AERIAL study, in partnership with The ORIGINS Project, endeavours to understand if exposures during pregnancy and early life can affect the cells lining the airways in newborns, and whether this is associated with the development of wheeze, allergy and asthma later in childhood.

Find out how you can get involved with our work at Phage WA.

Here are some of the most common questions about phage, phage therapy and antimicrobial resistance (AMR).

Antisense oligonucleotides are an emerging therapeutic option to treat diseases with known genetic origin. In the age of personalised medicines, antisense oligonucleotides can sometimes be designed to target and bypass or overcome a patient's genetic mutation, in particular those lesions that compromise normal pre-mRNA processing. Antisense oligonucleotides can alter gene expression through a variety of mechanisms as determined by the chemistry and antisense oligomer design.

On average, a person can expect to take more than 700 million breaths in their lifetime.

Cystic fibrosis (CF) is the most common life‐shortening genetic disease affecting children.

Learn more about all of the Clinical Trials, Platforms & Cohorts at the Wal-yan respiratory centre.

Respiratory disease is a global issue and international networks are critical to informing best-practice approaches to the clinical care and management of childhood respiratory health.